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population of patients with MPM. Although EPP patients had superior 
survival, much of this beneﬁt may be attributable to selection of pa-
tients with good prognosis at baseline. This review shows a non-signiﬁ-
cant trend to beneﬁt with the addition of EPP to these selected patients, 
and further study in a randomized setting is warranted.
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Background: Management strategies for MPM range from radical 
surgery with chemotherapy and radiation, to palliative measures only. A 
wide variation in practice is generally acknowledged, but evidence for 
this is anecdotal. A survey of Canadian thoracic surgeons (TS), radia-
tion (RO) and medical (MO) oncologists was performed to determine 
the pattern of practice across the country.
Methods: Surveys were devised to solicit opinions on issues related 
to management of MPM, including the role of surgery, radiotherapy 
(XRT) and chemotherapy (CTX). The survey questionnaires were 
distributed via electronic mail to members of the NCIC CTG who 
have participated in lung cancer trials, and the Canadian Association of 
Thoracic Surgeons.
Results: A total of 366 were surveyed in 2006, with responses received 
from 61 (16.7%): TS 16/76 (21%); RO 11/62 (17.7%); MO 34/228 
(14.9%). Respondent characteristics include: age, mean 46.7 yrs; 
gender (male/female/not reported), 40/18/3; years in practice, mean 
14.7 yrs; no. MPM cases seen in the last year, mean 7.5 (TS 14.9, RO 
3.6, MO 5.4). Routine methods of diagnosis employed: thoracoscopy, 
90%; minithoracotomy, 41%; closed pleural biopsy, 54.1%. Routine 
staging methods used: mediastinoscopy, 29.5%; thoracoscopy, 55.7%; 
CT, 100%; MRI, 21.3%; PET, 18%. In the last 2 years: no. TS who 
performed extrapleural pneumonectomy 7/16 (44%), pleurectomy 
5/16 (31%), either 10/16 (62.5%); no. RO who prescribed hemithorax 
XRT 6/11 (55%), XRT to biopsy/tube site 5/11 (45%); no. MO who 
prescribed CTX for disease control 33/34 (97%), as combined modality 
therapy 16/34 (47%).
Conclusions: The number of respondents is low, but likely reﬂects 
the size of the groups surveyed relative to selective referral patterns 
for MPM across the country. The methods used to make the diagnosis, 
and stage MPM are as expected, especially with respect to utilization 
of thoracoscopy and CT scan. There does appear to be a wide variation 
in practice as far as radical therapy, and prophylactic XRT to sites of 
chest instrumentation. However, CTX for disease control is routinely 
considered.
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Background: Cisplatin and pemetrexed (PEM) is the current stan-
dard in systemic therapy for malignant pleural mesothelioma (MPM) 
based on the landmark randomized trial reported in 2003. However, 
the combination of cisplatin and gemcitabine (GEM) was incorporated 
in to clinical practice following publication of promising phase II trial 
results in 1999. The impact of these platinum-based regimens is com-
pared in this review of practice in the province of British Columbia.
Methods: All cases of MPM diagnosed between 01 Jan 1999 and 31 
Dec 2005 were identiﬁed in a provincial registry using ICD-0 codes 
(9050/3, 9051/3, 9052/3, 9053/3). The clinical records of individuals 
referred to the BC Cancer Agency were reviewed, and those treated 
with a platinum analog plus GEM or PEM as ﬁrst-line therapy were 
included in survival analyses.
Results: During the study period, 278 patients were diagnosed with 
MPM. Of these, 81 were treated ﬁrst-line with a platinum plus GEM (n 
= 40) or PEM (n = 41). Characteristics of the entire cohort include: age 
at diagnosis, mean 65 yrs (median 66, range 43-84); gender, male 70 
(86%); laterality of disease, right-sided 50 (62%); histology, epithelioid 
or NOS 69 (85%). GEM was prescribed less often later in the study 
period. Fewer cycles with GEM were delivered (mean 3.8, median 4, 
range 1-6) as compared to PEM (5.2, 6, 1-8). Based on available data 
for survival from the ﬁrst day of treatment (GEM n = 38, PEM n = 
34), there was no difference in median survival, 1-yr and 2-yr survival 
rates: GEM 324 days, 45%, 21%; PEM 340 days, 46%, 24%. Similarly, 
no differences were seen based on survival from the recorded date of 
diagnosis, which included data for the entire cohort.
Conclusions: The survival outcomes with chemotherapy for MPM in 
this province-wide review are comparable to what has been reported 
in the medical literature. No difference is seen combining platinum 
analogs with GEM or PEM, although an analysis grouping patients by 
prognostic index was not performed. Platinum-based doublets might 
represent a therapeutic ceiling for cytotoxic chemotherapy, and it may 
be that further advances in systemic therapy for MPM can only be 
achieved with novel targeted agents.
